-
1 Comment
MediciNova, Inc is currently in a long term downtrend where the price is trading 21.9% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
MediciNova, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 50.5% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 17.8% to $-2M since the same quarter in the previous year.
Based on the above factors, MediciNova, Inc gets an overall score of 2/5.
| ISIN | US58468P2065 |
|---|---|
| Exchange | TSE |
| CurrencyCode | JPY |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 11B |
|---|---|
| PE Ratio | None |
| Target Price | 16.5 |
| Beta | 0.75 |
| Dividend Yield | None |
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4875.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
